Healthcare Stocks Under Review -- Exact Sciences, Great Basin Scientific, Agilent Technologies, and Thermo Fisher Scientific

Sep 08, 2016, 07:30 ET from Chelmsford Park SA

NEW YORK, September 8, 2016 /PRNewswire/ --

The Medical Laboratories market continues to grow at a fast pace due to scientific advances and aging population. This segment includes bacteriological, histological, pathological and chemical analysis, urinalysis, and dental and medical X-rays. Stocks under assessment on today are: Exact Sciences Corp. (NASDAQ: EXAS), Great Basin Scientific Inc. (NASDAQ: GBSN), Agilent Technologies Inc. (NYSE: A), and Thermo Fisher Scientific Inc. (NYSE: TMO). Learn more about these stocks by downloading their free research reports in PDF format at:

Exact Sciences  

On Wednesday, shares in Exact Sciences Corp. recorded a trading volume of 2.61 million shares. The stock ended the day at $19.43, climbing 2.16%. The Company's shares have gained 0.21% in the last one month, 162.57% over the previous three months, and 110.51% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 18.22% and 103.60%, respectively. Furthermore, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers, have a Relative Strength Index (RSI) of 57.58.

On August 11th, 2016, Exact Sciences announced that Health Care Service Corp., the nation's fourth largest health insurer, and Florida Blue recently updated their medical policies to cover Cologuard. With these policy updates, 80 million people are insured by commercial plans with positive medical policies regarding Cologuard. Including Medicare, Cologuard is now covered for 62 percent of its total target population. Sign up and read the free research report on EXAS at:

Great Basin Scientific  

Salt Lake City, Utah-based Great Basin Scientific Inc.'s stock finished yesterday's session 19.95% lower at $0.15. A total volume of 11.92 million shares was traded, which was above their three months average volume of 3.80 million shares. The Company's shares are trading below their 50-day moving average by 78.49%. Furthermore, shares of Great Basin Scientific, which develops and commercializes molecular diagnostic systems that are designed to test hospital-acquired infections, have an RSI of 17.33.

On September 06th, 2016, the company announced that it received a delisting warning from Nasdaq after 30 consecutive days of its common stock trading below the $1 minimum bid price, making it non-compliant with Nasdaq Listing Rule 5550(a)(2). The Company will have until February 27th, 2017 to regain compliance by maintaining a minimum bid price of $1 for a minimum 10 consecutive days at any time within the next 180 days. Great Basin Scientific stated that it has already taken definitive steps to comply with the Listing Rule, in that it is seeking shareholders' approval for a reverse stock split during the Annual Meeting of Stockholders being held on September 12th, 2016. The complimentary research report on GBSN can be downloaded at:

Agilent Technologies  

At the closing bell on Wednesday, shares in Santa Clara, California headquartered Agilent Technologies Inc. rose 0.34%, ending the day at $47.11. The stock recorded a trading volume of 1.54 million shares. The Company's shares have advanced 2.35% in the previous three months and 13.30% since the start of this year. The stock is trading 1.03% above its 50-day moving average and 12.16% above its 200-day moving average. Moreover, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have an RSI of 50.17.

On August 30th, 2016, Agilent Technologies unveiled a new addition to its industry-leading line of gas chromatographs. The Agilent Intuvo 9000 GC solution offers users new innovative technology that will help laboratories meet operational, scientific and financial goals. Register for free on and access the latest report on A at:

Thermo Fisher Scientific  

Waltham, Massachusetts headquartered Thermo Fisher Scientific Inc.'s stock ended the day 0.33% lower at $150.50. A total volume of 1.52 million shares was traded, which was above their three months average volume of 1.31 million shares. The Company's shares have gained 6.32% on an YTD basis. The stock is trading 4.85% above its 200-day moving average. Additionally, shares of Thermo Fisher Scientific, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics worldwide, have an RSI of 37.86.

On September 7th, 2016, the company announced that it has priced an offering of €1.0 billion aggregate principal amount of its 0.750% senior notes due 2024 and €600 million aggregate principal amount of its 1.375% senior notes due 2028 at the issue prices of 99.122% of the principal amount and 99.748% of the principal amount, respectively. The issuance of the notes is expected to close on or about September 12th, 2016. Thermo Fisher intends to use the net proceeds of the offering to finance a portion of the estimated $4.2 billion purchase price for its acquisition of FEI Company and to pay certain associated costs. Get free access to your research report on TMO at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA